Literature DB >> 10882147

Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology.

S A Kemink1, A R Hermus, L M Swinkels, J A Lutterman, A G Smals.   

Abstract

The objective was to evaluate the prevalence and severity of osteopenia in patients with uncomplicated insulin-dependent diabetes mellitus (IDDM) and to obtain more information on the pathophysiology of diabetic osteopenia. In 35 patients with uncomplicated IDDM (21 men and 14 women; age 37.6+/-9.9 yr; duration of disease 8.5+/-3.5 years) bone mineral density was measured by dual energy X-ray absorptiometry (DEXA). In addition, markers of bone formation [plasma insulin-like growth factor I (IGF-I), serum alkaline phosphatase (ALP), serum bone alkaline phosphatase (BAP) and serum osteocalcin] and bone resorption [urinary excretion of calcium and of the cross-linked N-telopeptide of type 1 collagen, both corrected for the excretion of creatinine] were measured in the diabetic patients and in 33 healthy controls, matched for sex, age, height, weight and body mass index (BMI). In 67% of the diabetic men and 57% of the diabetic women osteopenia of the femoral neck and/or the lumbar spine (T-value < or = -1 SD) was present. Fourteen percent of the male patients, but none of the female patients, met the criteria for osteoporosis (T-value < or = -2.5 SD). In the whole group of diabetic patients the mean plasma IGF-I level tended to be lower (p<0.10) as compared to that in the controls. In the diabetic patients with femoral neck osteopenia, the mean plasma IGF-I level was significantly lower (p<0.05) than in those without osteopenia at this site. There were no differences in the mean serum ALP, BAP and osteocalcin levels between the diabetic patients and the controls, nor between the diabetic patients with and without femoral neck osteopenia. Considering only the male diabetic patients, significantly lower mean plasma IGF-I (-26%), serum ALP (-24%) and serum osteocalcin (-38%) levels were present in the patients with femoral neck osteopenia than in those without osteopenia at this site, suggesting lowered bone formation. The bone resorption markers were similar in all (sub)groups of diabetic patients and not different between diabetic patients and controls. Bone mineral density (BMD) did not correlate with plasma levels of glycosylated hemoglobin (HbA1c). BMD values were not related to any of the bone resorption or formation markers, except for plasma IGF-I both in the femoral neck (r=+0.38, p=0.026) and the lumbar spine (r=+0.34, p=0.043). Our data demonstrate that at least in male patients with IDDM, osteopenia is the consequence of a lowered bone formation with a predominance of bone resorption over formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882147     DOI: 10.1007/BF03343726

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  28 in total

1.  Mineral metabolism and bone mass at peripheral and axial skeleton in diabetes mellitus.

Authors:  J Auwerx; J Dequeker; R Bouillon; P Geusens; J Nijs
Journal:  Diabetes       Date:  1988-01       Impact factor: 9.461

2.  Is diabetic osteoporosis due to microangiopathy?

Authors:  S Wientroub; D Eisenberg; R Tardiman; S L Weissman; R Salama
Journal:  Lancet       Date:  1980-11-01       Impact factor: 79.321

3.  Predictors of ankle and foot fractures in older women. The Study of Osteoporotic Fractures Research Group.

Authors:  D G Seeley; J Kelsey; M Jergas; M C Nevitt
Journal:  J Bone Miner Res       Date:  1996-09       Impact factor: 6.741

4.  Advantages of paper chromatography as a preparative step in the assay of 1,25-dihydroxyvitamin D.

Authors:  H J van Hoof; L M Swinkels; J J van Stevenhagen; H van den Berg; H A Ross; T J Benraad
Journal:  J Chromatogr       Date:  1993-11-17

5.  Vitamin D metabolites and their binding protein in adult diabetic patients.

Authors:  B L Nyomba; R Bouillon; M Bidingija; K Kandjingu; P De Moor
Journal:  Diabetes       Date:  1986-08       Impact factor: 9.461

6.  An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus.

Authors:  S J Gallacher; J A Fenner; B M Fisher; J D Quin; W D Fraser; F C Logue; R A Cowan; I T Boyle; A C MacCuish
Journal:  Diabet Med       Date:  1993-03       Impact factor: 4.359

7.  Increasing serum osteocalcin after glycemic control in diabetic men.

Authors:  S Sayinalp; O Gedik; Z Koray
Journal:  Calcif Tissue Int       Date:  1995-12       Impact factor: 4.333

8.  Bone loss in diabetes: effects of metabolic state.

Authors:  P McNair; S Madsbad; C Christiansen; M S Christensen; O K Faber; C Binder; I Transbøl
Journal:  Diabetologia       Date:  1979-11       Impact factor: 10.122

9.  Diabetic bone disease. Low turnover osteoporosis related to decreased IGF-I production.

Authors:  R Bouillon
Journal:  Verh K Acad Geneeskd Belg       Date:  1992

10.  Whole body composition and regional bone mass in women with insulin-dependent diabetes mellitus.

Authors:  J E Compston; E M Smith; C Matthews; P Schofield
Journal:  Clin Endocrinol (Oxf)       Date:  1994-09       Impact factor: 3.478

View more
  86 in total

Review 1.  Osteoporosis and diabetes mellitus.

Authors:  Angela M Inzerillo; Solomon Epstein
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 2.  Immunotherapy for type 1 diabetes.

Authors:  Davide Frumento; Moufida Ben Nasr; Basset El Essawy; Francesca D'Addio; Gian Vincenzo Zuccotti; Paolo Fiorina
Journal:  J Endocrinol Invest       Date:  2017-03-04       Impact factor: 4.256

3.  Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation.

Authors:  Lindsay M Coe; Srinivasan Arjun Tekalur; Yutian Shu; Melissa J Baumann; Laura R McCabe
Journal:  J Cell Physiol       Date:  2015-08       Impact factor: 6.384

4.  Hyperglycemia diverts dividing osteoblastic precursor cells to an adipogenic pathway and induces synthesis of a hyaluronan matrix that is adhesive for monocytes.

Authors:  Aimin Wang; Ronald J Midura; Amit Vasanji; Andrew J Wang; Vincent C Hascall
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

5.  Effect of exercise on bone in poorly controlled type 1 diabetes mediated by the ActRIIB/Smad signaling pathway.

Authors:  Jin Yang; Lijun Sun; Xiushan Fan; Bo Yin; Yiting Kang; Liang Tang; Shucheng An
Journal:  Exp Ther Med       Date:  2018-08-13       Impact factor: 2.447

Review 6.  A new perspective on mechanisms governing skeletal complications in type 1 diabetes.

Authors:  Zeynep Seref-Ferlengez; Sylvia O Suadicani; Mia M Thi
Journal:  Ann N Y Acad Sci       Date:  2016-08-29       Impact factor: 5.691

7.  MiR-155 inhibition alleviates suppression of osteoblastic differentiation by high glucose and free fatty acids in human bone marrow stromal cells by upregulating SIRT1.

Authors:  Bo Qu; Jun He; Zhimou Zeng; Hongsheng Yang; Zhanli Liu; Zongrui Cao; Hua Yu; Wen Zhao; Xianming Pan
Journal:  Pflugers Arch       Date:  2020-04-04       Impact factor: 3.657

8.  Contributions of the Insulin/Insulin-Like Growth Factor-1 Axis to Diabetic Osteopathy.

Authors:  John L Fowlkes; Clay Bunn R; Kathryn M Thrailkill
Journal:  J Diabetes Metab       Date:  2011-11-25

9.  Spontaneous bone loss in RIP-iNOS transgenic mouse: a mouse model for diabetes-mediated osteopenia/osteoporosis.

Authors:  Qing-Sheng Mi; Sheng-Li Yan; Zai-Zhao Wang; Ke-Hong Ding; Changgui Li; Luan Wang; Li Zhou; Yasuhiko Yamamoto; Hiroshi Yamamoto; Hiroshi Okamoto; Carlos Isales
Journal:  Cell Cycle       Date:  2009-12-21       Impact factor: 4.534

10.  L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats.

Authors:  P Pennisi; G Clementi; A Prato; T Luca; G Martinez; R A Mangiafico; I Pulvirenti; F Muratore; C E Fiore
Journal:  J Endocrinol Invest       Date:  2009-05-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.